TRANSCEND is a partnership between the Koch Institute and Janssen Pharmaceuticals, Inc (formerly known as Ortho-McNeil-Janssen Pharmaceuticals, Inc). Our initial five-year collaborative agreement fosters oncology research and technology development in cancer diagnostics (predictive biomarkers, surrogate endpoints, and CTCs), novel therapeutic targets, drug delivery systems, cancer immunotherapies, and murine disease models to study pre-malignancies, tumor progression, and target validation.

A Joint Scientific Steering Committee composed of Koch Institute faculty members and Janssen Pharmaceuticals, Inc senior management employees jointly reviews and selects proposals from MIT researchers for funding. In addition, there is a provision for visiting scientists from Janssen Pharmaceuticals, Inc to participate in projects within the investigators’ laboratories at the Koch Institute.